172 related articles for article (PubMed ID: 25484311)
1. Cellular Therapies Clinical Research Roadmap: lessons learned on how to move a cellular therapy into a clinical trial.
Ouseph S; Tappitake D; Armant M; Wesselschmidt R; Derecho I; Draxler R; Wood D; Centanni JM
Cytotherapy; 2015 Apr; 17(4):339-43. PubMed ID: 25484311
[TBL] [Abstract][Full Text] [Related]
2. The National Heart, Lung, and Blood Institute-funded Production Assistance for Cellular Therapies (PACT) program: Eighteen years of cell therapy.
El Fiky A; Ibenana L; Anderson R; Hare JM; Khan A; Gee AP; Rooney C; McKenna DH; Gold J; Kelley L; Lundberg MS; Welniak LA; Lindblad R
Clin Transl Sci; 2021 Nov; 14(6):2099-2110. PubMed ID: 34286927
[TBL] [Abstract][Full Text] [Related]
3. Production Assistance for Cellular Therapies (PACT): four-year experience from the United States National Heart, Lung, and Blood Institute (NHLBI) contract research program in cell and tissue therapies.
Reed W; Noga SJ; Gee AP; Rooney CM; Wagner JE; McCullough J; McKenna DH; Whiteside TL; Donnenberg AD; Baker AK; Lindblad RW; Wagner EL; Mondoro TH
Transfusion; 2009 Apr; 49(4):786-96. PubMed ID: 19170985
[TBL] [Abstract][Full Text] [Related]
4. The investigator-sponsored IND in clinical trials.
Haakenson C; Fye CL; Sather MR; Toussaint DJ
Control Clin Trials; 1987 Jun; 8(2):101-9. PubMed ID: 3608504
[TBL] [Abstract][Full Text] [Related]
5. Topical delivery of cultured stem cells to human non-healing wounds: GMP facility development in an academic setting and FDA requirements for an IND and human testing.
Yufit T; Carson P; Falanga V
Curr Drug Deliv; 2014; 11(5):572-81. PubMed ID: 23517627
[TBL] [Abstract][Full Text] [Related]
6. Accommodating clinical trials and other externally manufactured cellular therapy products: challenges, lessons learned and creative solutions.
Jackson MR
Cytotherapy; 2022 Jan; 24(1):37-44. PubMed ID: 34305008
[TBL] [Abstract][Full Text] [Related]
7. Investigational new drugs submitted to the Food and Drug Administration that are placed on clinical hold: the experience of the Office of Cellular, Tissue and Gene Therapy.
Wonnacott K; Lavoie D; Fiorentino R; McIntyre M; Huang Y; Hirschfeld S
Cytotherapy; 2008; 10(3):312-6. PubMed ID: 18418776
[TBL] [Abstract][Full Text] [Related]
8. Good manufacturing practice requirements for the production of tissue vitrification and warming and recovery kits for clinical research.
Laronda MM; McKinnon KE; Ting AY; Le Fever AV; Zelinski MB; Woodruff TK
J Assist Reprod Genet; 2017 Feb; 34(2):291-300. PubMed ID: 27900615
[TBL] [Abstract][Full Text] [Related]
9. Intestinal organoids: roadmap to the clinic.
Kasendra M; Troutt M; Broda T; Bacon WC; Wang TC; Niland JC; Helmrath MA
Am J Physiol Gastrointest Liver Physiol; 2021 Jul; 321(1):G1-G10. PubMed ID: 33950707
[TBL] [Abstract][Full Text] [Related]
10. Food and Drug Administration requirements for testing and approval of new radiopharmaceuticals.
Harapanhalli RS
Semin Nucl Med; 2010 Sep; 40(5):364-84. PubMed ID: 20674596
[TBL] [Abstract][Full Text] [Related]
11. Regulatory decision strategy for entry of a novel biological therapeutic with a clinically unmonitorable toxicity into clinical trials: pre-IND meetings and a case example.
Black LE; Bendele AM; Bendele RA; Zack PM; Hamilton M
Toxicol Pathol; 1999; 27(1):22-6. PubMed ID: 10367668
[TBL] [Abstract][Full Text] [Related]
12. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
13. Current regulatory issues in cell and tissue therapy.
Burger SR
Cytotherapy; 2003; 5(4):289-98. PubMed ID: 12944234
[TBL] [Abstract][Full Text] [Related]
14. INGN 201: Ad-p53, Ad5CMV-p53, Adenoviral p53, INGN 101, p53 gene therapy--Introgen, RPR/INGN 201.
BioDrugs; 2003; 17(3):216-22. PubMed ID: 12749760
[TBL] [Abstract][Full Text] [Related]
15. The IND application.
Ferkany JW; Williams M
Curr Protoc Pharmacol; 2008 Sep; Chapter 9():Unit 9.10. PubMed ID: 22294234
[TBL] [Abstract][Full Text] [Related]
16. Good Manufacturing Practice (GMP) Translation of Advanced Cellular Therapeutics: Lessons for the Manufacture of Erythrocytes as Medicinal Products.
McGowan NWA; Campbell JDM; Mountford JC
Methods Mol Biol; 2018; 1698():285-292. PubMed ID: 29076098
[TBL] [Abstract][Full Text] [Related]
17. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
18. Product Development within the National Institutes of Health Radiation and Nuclear Countermeasures Program.
Cassatt DR; DiCarlo AL; Molinar-Inglis O
Radiat Res; 2024 May; 201(5):471-478. PubMed ID: 38407357
[TBL] [Abstract][Full Text] [Related]
19. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
20. Development of an NIH consortium for preclinicAl AssESsment of CARdioprotective therapies (CAESAR): a paradigm shift in studies of infarct size limitation.
Lefer DJ; Bolli R
J Cardiovasc Pharmacol Ther; 2011; 16(3-4):332-9. PubMed ID: 21821536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
